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Emmanuel Zorn, Mehrdad Mohseni, Haesook Kim, Fabrice Porcheray, Allison Lynch,
Roberto Bellucci, Christine Canning, Edwin P. Alyea, Robert J. Soiffer, Jerome Ritz1 1 1CD4 CD25 FOXP3 regulatory T cells (Treg) successfully control graft-versus-host-disease (GVHD) in
animal models. In humans, incomplete reconstitution of Treg after allogeneic hematopoietic stem cell trans-
plantation (HSCT) has been associated with chronic GVHD (cGVHD). Recent studies have demonstrated
that interleukin (IL)-2 infusions expand Treg in vivo. However, the effectiveness of this therapy depends
on the number of cells capable of responding to IL-2. We examined the effect of low-dose IL-2 infusions
on Treg populations after HSCT in patients who also received infusions of donor CD41 lymphocytes. Uti-
lizing FOXP3 as a Treg marker, we found that patients who received CD41DLI concomitantly with IL-2 had
greater expansion of Treg compared to patients who received IL-2 (P 5 .03) or CD41DLI alone (P 5 .001).
FOXP3 expression correlated with absolute CD41CD251 cell counts. Moreover, expanded CD41CD251
T cells displayed normal suppressive function and treatment with CD41DLI and IL-2 was not associated
with GVHD. This study suggests that administration of low-dose IL-2 combined with adoptive CD41 cellular
therapy may provide a mechanism to expand Treg in vivo.
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topoietic stem cell transplantationINTRODUCTION subsequent development of chronic GVHD [6,7].CD41CD251FOXP31 regulatory T cells (Treg)
play a critical role in controlling immune reactions fol-
lowing allogeneic hematopoietic stem cell transplanta-
tion (HSCT) [1]. In mice, infusion of purified Treg at
the time of transplant can prevent the development of
lethal graft-versus-host disease (GVHD), whereas de-
pletion of these cells worsens GVHD [2-5]. In most
experimental models, prevention of GVHD is
achieved while preserving a beneficial graft-versus-
leukemia (GVL) effect [3-5]. In humans, poor recon-
stitution of Treg after HSCT correlates with theivision ofHematologicMalignancies, Dana-Farber Can-
stitute, Harvard Medical School, Boston, Massachusetts.
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6/j.bbmt.2008.12.494Taken together, these findings suggest that methods
to increase the number of Treg in vivo may provide
a new approach for either prevention or treatment of
GVHD following allogeneic HSCT [1,8,9]. Based on
murine models, several investigators have proposed
that adoptive therapy with purified Treg that have pre-
viously been expanded in vitro may be able to prevent
or treat GVHD [10,11]. Recent clinical studies have
also shown that IL-2 therapy induces the selective ex-
pansion of Treg following HSCT as well as in patients
with solid tumors [12-14]. The effect of IL-2, however,
depends on the presence of sufficient numbers of Treg
capable of responding to cytokine stimulation. Com-
bining adoptive cellular therapy together with IL-2
administration could therefore represent a strategy to
effectively expand Treg in patients where these cells
are severely reduced. In the present study, we exam-
ined the modulation of Treg in patients who received
concomitant CD8-depleted donor lymphocyte infu-
sion (CD41DLI) together with prolonged low-dose
IL-2 following HSCT. We provide evidence that
this combined therapy substantially expands Treg in
vivo to a level greater than CD41DLI or low-dose
IL-2 alone.
Table 1. Clinical Summary of DLI and IL-2 Therapy
Treatment Patient Diagnosis Age
DLI
Dose (CD4+
Cells/kg)
Dose and
Route of IL-2
(IU/m2/Day)
Duration
of IL-2
Disease Status
at Start of
Treatment
Time from HSCT
to Therapy
(Months)
Response
to DLI GVHD
DLI + IL-2 1 AML 49 6.7  107 6  105,SC* 5 weeks Relapse 8 N N
2 ALL 35 3  107 6  105,SC 12 weeks Relapse 60 N N
3 AML 59 8.2  107 6  105,SC 12 weeks Relapse 17 N N
4 AML 63 1  108 6  105,SC 12 weeks Relapse 8 N N
5 MM 58 3  107 6  105, SC 12 weeks Relapse 48 N N
IL-2 6 NHL 27 N/A 2  105, IV† 13 weeks Remission 1.5 N/A N
7 AML 37 N/A 2  105, IV 12 weeks Remission 2 N/A N
8‡ ALL 40 N/A 2  105, IV 12 weeks Remission 4 N/A N
9 CML 31 N/A 2 -4  105, IV 12 weeks Remission 2 N/A N
10 AML 43 N/A 2  105, IV 12 weeks Remission 1.5 N/A N
DLI 11 AML 46 1  108 N/A N/A Relapse 27 N N
12§ CML 49 3  107,1  108 N/A N/A Relapse 17 N N
13 CML 41 3  107 N/A N/A Relapse 22 Y Y
14 CML 48 3  107 N/A N/A Relapse 26 N N
*Subcutaneous.
†Intravenous.
‡Patient 8 received autologous HSCT.
§Patient 12 received two DLI.
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Patients and Samples
Patients included in this study were enrolled in
clinical protocols approved by the Dana-Farber Can-
cer Institute investigational review board (IRB). All
patients received myeloablative conditioning and pe-
ripheral blood mononuclear cells (PBMC) were iso-
lated from blood before and after treatment and
cryopreserved. Patient and treatment characteristics
are summarized in Table 1.
Quantitative Polymerase Chain Reaction (PCR)
Quantitative PCR for FOXP3 has been described
previously [7,14]. Briefly, experiments were performed
using universal PCRMaster Mix (Applied Biosystems,
Foster City, CA) and FOXP3-specific primers and
probe. Results were normalized based on the amplifi-
cation of TFRC (CD71, transferrin receptor).
Immunofluorescence Analysis
Intracellular staining of FOXP3, was performed
using a commercially available kit (eBioscience,
San Diego, CA). Absolute numbers of CD41 and
CD41CD251 lymphocytes were calculated based on
total lymphocyte counts and phenotypic data.
Suppression of T Cell Proliferation by Treg
Standard suppression assays were performed as de-
scribed previously [7]. Briefly, CD41CD252 and
CD41CD251 cells were purified from patient samples
by cell sorting and incubated either alone or together
(ratio of 1:1) in the presence of soluble anti-CD3
(OKT3; 1 mg/mL) and irradiated allogeneic PBMC
(1  104 cells/well). Responder cell proliferation was
measured after 6 days.Statistical Analysis
FOXP3 expression level was log-transformed (base
10). Student t-test was used for 2-sample comparisons.
Linear regression models were fit to examine the
group effect after adjusting for age, sample collection
days, time fromHSCT/DLI to therapy, IL-2 dose, du-
ration of IL-2, and DLI dose.RESULTS
Patient Groups
In the present study we investigated whether
a combination of IL-2 and adoptive cellular therapy
could enhance the expansion of Treg in vivo. We ex-
amined changes in circulating Treg in 3 groups of pa-
tients who had previously undergone allogeneic
HSCT following a myeloablative conditioning regi-
men consisting of cyclophosphamide and total body ir-
radiation. Patient characteristics are summarized in
Table 1. The first group includes 5 patients with re-
lapsed hematologic malignancy who received CD8-T
cell-depleted DLI (CD41 DLI) and low-dose IL-2.
These patients received defined doses of CD41 DLI
(3  107 to 1  108 CD41 cells/kg) followed by daily
administration of 6  105 IU/m2 IL-2 for 12 continu-
ous weeks. One patient had to discontinue treatment
after 5 weeks for accelerated disease (patient 1). This
Phase I trial was designed to evaluate safety of the com-
bined therapy as a primary endpoint and antitumor ef-
fect of the combined therapy as a secondary endpoint.
The second group of 5 patients received lower doses of
IL-2 (2  105 IU/m2/day) for 12 to 13 continuous
weeks. For these patients, IL-2 was administered rela-
tively early after CD6-depleted allogeneic transplant
when leukemia was in remission with the intent to in-
crease the GVL effect and prevent relapse [15,16].
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Figure 1. Increased FOXP3 gene expression following CD41 DLI plus
low-dose IL-2. FOXP3 expression was assessed by real-time PCR in
PBMC from patients who received CD41 DLI (black lines), low-dose
IL-2 (blue lines), or combined CD41 DLI and low-dose IL-2 (red lines).
FOXP3 expression levels were normalized based on the expression of
TFRC (transferrin receptor).
384 Biol Blood Marrow Transplant 15:382-388, 2009E. Zorn et al.Patients were monitored for safety and the effects of
IL-2 therapy on reconstitution of NK cells (CD561)
and T cells (CD31CD41 and CD31CD81) in periph-
eral blood. Group 3 was comprised of 4 patients who
received CD41 DLI alone without IL-2 for relapsed
leukemia. This Phase I trial was undertaken to evaluate
the safety of escalating doses of CD41 DLI as well
as efficacy of DLI. None of the patients included in
the 3 groups had prior episodes of acute GVHD
(aGVHD) or chronic GVHD (cGVHD). As shown
in Table 1, times from HSCT to therapy varied for
the different groups. Patients who received IL-2 alone
were treated prophylactically beginning at 6 to 12
weeks posttransplant. In contrast, patients who re-
ceived DLI with or without IL-2 were treated for
relapsed leukemia at later times posttransplant. Toxic-
ity specifically associated with IL-2 administration was
minimal including transient fatigue, fever, nausea,
myalgia, and rash, and was consistent with previous
findings [17,18]. CD41 DLI was also well tolerated
and did not lead to any severe side effects as previously
reported in similar trials [19,20]. None of the patients
examined in this study developed GVHD following
IL-2 infusion or CD41DLI.One patient who received
CD41 DLI alone developed GVHD after treatment.Increase in FOXP3 Gene Expression following
CD41 DLI and IL-2 Therapy
Tomeasure changes in Treg during therapy we as-
sessed FOXP3 gene expression by quantitative PCR in
PBMC collected before and after treatment. Results
are reported in Figure 1 for the 3 patient groups. As de-
picted in this figure, concomitant administration of
low-dose IL-2 andCD41DLI (red lines) induced a sig-
nificant increase in FOXP3 gene expression levels
when compared to CD41DLI only (black lines; Stu-
dent t-test for largest value, P 5 .001) or low-dose
IL-2 only (blue lines; Student t-test for largest value,
P5 .03). Increase in FOXP3 gene expression following
CD41DLI 1 IL-2 was also confirmed in a linear re-
gression model for which age, sampling time, time
from HSCT to therapy, DLI and IL-2 doses as well
as duration of IL-2 therapy were adjusted (P\ .001).
Increased FOXP3 gene expression was not seen in
any of the patients who only received CD41DLI. In
addition, compared to previously published reports,
IL-2 had a relatively weak effect on FOXP3 gene ex-
pression in the 5 patients who only received this treat-
ment [12-14]. This was likely because of low numbers
of CD41CD251T cells in these patients prior to ther-
apy early after stem cell transplantation. The median
absolute CD41CD251 T cell counts in these patients
before treatment was only 7.5 6 3.8 cells/mL com-
pared to approximately 200 CD41CD251 cells/mL
in the peripheral blood of healthy donors. Only 1 pa-
tient (patient 4) did not experience an increase inFOXP3 gene expression following CD41DLI 1 IL-2.
This patient had relapsed AML at the time therapy
was started.CD41 DLI 1 IL-2 Induces Peripheral Treg
Expansion and Increased FOXP3 Protein
Expression in Peripheral Treg
FOXP3 protein expression in peripheral blood
lymphocytes was also examined by flow cytometry
before and after CD41 DLI and IL-2. As shown in
Figure 2, increased FOXP3 gene expression for the 4
patients in group 1 was confirmed by an expansion of
CD41T cells expressing intracellular FOXP3 protein.
Staining intensity for FOXP3 was increased for all
CD41CD251 T cells, indicating that IL-2 also in-
duced upregulation of FOXP3 gene expression at the
single cell level.FOXP3 Gene Expression Levels Correlate with
Absolute CD41CD251 T Cell Counts
Consistent with the IL-2 effect on Treg expansion,
we observed a highly significant correlation between
FOXP3 gene expression levels and absolute
CD41CD251 counts (Spearman correlation coeffi-
cient r 5 0.79, P 5 .0003; Figure 3A). These results
provided additional support for assessing FOXP3
gene expression as a surrogate marker for Treg popu-
lations. Correlation between FOXP3 gene expression
levels and CD41 counts was also significant in these
patients (r 5 .76, P 5 .0006; Figure 3B).
Figure 2. Intracellular staining for FOXP3 protein in patients who received CD41DLI and IL-2. Patient PBMC were tested for expression of cell mem-
brane CD4 and intracellular FOXP3. Samples were collected before patients received CD41DLI and IL-2 and between 13 to 77 days after starting ther-
apy. Dot-plots are shown after gating on lymphocyte populations.
Biol Blood Marrow Transplant 15:382-388, 2009 385Combined CD41 DLI and IL-2 Therapy Expands TregCD41DLI1 IL-2 ExpandedTreg Exhibit Normal
Immune Suppressive Function In Vivo
To determine whether Treg that expanded in vivo
after CD41DLI and IL-2 maintained their suppressive
function, we tested purified CD41CD251 cells from
these patients for their ability to inhibit proliferation
of autologous CD41CD252T cells in vitro. As shown
in Figure 4, Treg purified from patient samples col-
lected during combined therapy at a time when
FOXP3 gene expression was increased, displayed sim-ilar levels of suppressive function as Treg isolated from
healthy donors.
DISCUSSION
The present studies demonstrate that the addition
of low-dose IL-2 to CD41 lymphocyte infusions re-
sults in a marked expansion of CD41CD251FOXP31
regulatory T cells. The increase was significantly
greater than that observed in patients receiving rIL-2
alone. As this latter group of patients received a lower
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Figure 3. Correlation of FOXP3 gene expression and CD41CD251 Treg and total CD4 T cells in peripheral blood after CD41DLI and IL-2. (A) FOXP3
gene expression (circles) was assessed by quantitative PCR in PBMC collected from patients who received CD41DLI1 IL-2 and is shown together with
absolute blood CD41CD251 T cell counts (triangles; cells/mL). Spearman correlation coefficient r5 0.79, P5 .0003. (B) FOXP3 gene expression is de-
picted (circles) together with absolute blood CD41 T cell counts (squares; cells/mL) for all patients treated with CD41DLI1 IL-2. Spearman correlation
coefficient r 5 .76, P 5 .0006.
386 Biol Blood Marrow Transplant 15:382-388, 2009E. Zorn et al.dose of IL-2 that patients who received both DLI
and IL-2, it is possible that the dose of IL-2 contrib-
uted to the different effects in these 2 groups of pa-
tients. In contrast, patients who received CD8
depleted DLI alone had no increase in circulating
CD41CD251FOXP31 regulatory T cells whatsoever.These results provide a framework in which allogeneic
Tregs can be expanded in vivo without the need for
long term ex vivo culture.
It is noteworthy that previous studies from our
institution have documented that low-dose IL-2
can be safely administered to patients early after
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Figure 4. Suppressive activity of CD41CD251 Treg following IL-2 and
CD41 DLI combined therapy. Suppressive activity of purified
CD41CD251 T cells was assessed for patients 1, 2, 3, and 5 using sam-
ples collected after DLI and during IL-2 treatment. Suppression by Treg
purified from 4 healthy donors was also measured. Solid lines represent
median values for the 2 groups.
Biol Blood Marrow Transplant 15:382-388, 2009 387Combined CD41 DLI and IL-2 Therapy Expands TregT cell-depleted allogeneic transplantation without
inducing aGVHDor cGVHD.We previously demon-
strated that such treatment dramatically expands
CD561CD32 NK cells, but also CD41CD251
FOXP31 regulatory T cells [14,17,18]. The patients
receiving CD81 depleted DLI plus IL-2 also did not
develop any GVHD.Nor was any GVL activity noted.
None of the patients receiving CD8-depleted DLI
plus IL-2 achieved significant tumor responses. It is
possible that the antitumor effect of DLI was dimin-
ished by the expansion of Treg, although all of these
patients had advanced hematologic malignancies prior
to treatment. Although the original intent of this clin-
ical trial was to augment cytotoxic effector activity, the
combination of CD8-depleted DLI and low-dose IL-2
appears to have served to instead expand cells with po-
tent immune suppressive properties.We have reported
on the expansion of effector T cells with potent antitu-
moral activity following CD41DLI [21]. It is possible
that expanded Treg in patients who received the com-
bined therapymay have diminished the efficacy of such
GVL effector cells.
Other studies published by Ahmadzadeh et al. and
Zhang et al. [12-14] have also demonstrated the capac-
ity of IL-2 therapy to expand humanTreg in vivo using
higher doses and intermittent therapy with IL-2. We
have also reported similar expansion of Treg in vivo
following administration of low-doses of IL-2 compa-
rable to the doses given to DLI recipients in this study
[14]. IL-2 directly induces the upregulation of FOXP3
gene expression through the phosphorylation of
STAT proteins downstream of the IL-2 receptor
that subsequently translocate to the nucleus and bind
to regulatory motifs located in the first intron of theFOXP3 gene [14]. This signaling pathway appears ac-
tive in CD41CD251Treg that already express FOXP3
but not in CD41CD252 cells. Consistent with this
mechanism, the intensity of FOXP3 intracellular
staining in Treg increased following IL-2 treatment,
reflecting an upregulation of gene expression at the
single cell level. The effect of IL-2 therapy is therefore
dependent on preexisting populations of Treg in
treated patients. Following HSCT, T cell populations
are often reduced because of the preparative regimen
and concomitant administration of calcineurin inhibi-
tors. Our studies suggest that a combination of both
CD8-T cell-depleted DLI to replenish CD41 T cell
pools together with administration of low dose IL-2
can more effectively expand Treg in vivo.
Recent investigations have revealed a crucial role
for Treg in controlling immune responses post-
HSCT and especially the development of GVHD. In
animal models, infusion of Treg at the time of stem
cell infusion or immediately following transplantation
successfully prevented GVHD [2,3,5]. In most studies,
this was achieved while maintaining the beneficial
GVL effect. In the autologous setting, however,
Treg have been shown on numerous occasions to im-
pair antitumor immunity [22]. In humans, we and
others have shown that poor Treg reconstitution cor-
relates with cGVHD [6,7,23,24]. Treg cellular therapy
could thus be utilized to replenish Treg pools in vivo
and prevent or even correct GVHD. A number of stud-
ies have addressed the feasibility of purifying and ex-
panding human Treg ex vivo to use these cells for
adoptive therapy [10,25,26]. Overall, our retrospective
study suggests that combined therapy with CD41 do-
nor lymphocytes and low-dose IL-2 may be an alterna-
tive strategy for expanding Treg in vivo. This strategy
does not rely on the purification and selective expan-
sion of Treg in vitro. Furthermore, previous findings
that combined CD41DLI and low-dose IL-2 have
not been associated with GVHD suggest that this ap-
proach could be safely tested in clinical trials with care-
ful monitoring of immunological effects and toxicity.ACKNOWLEDGMENTS
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